Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study

Find Full text
Publication year
2019
Author(s)
Paul, C.
Griffiths, C.E.
Kerkhof, P.C.M. van de
Puig, L.
Dutronc, Yves
Henneges, Carsten
Hollister, Kristin
Reich, K.
Source
Journal of the American Academy of Dermatology, 80, 1, (2019), pp. 70-+
ISSN
DOI
Publication type
Article / Letter to editor
Please use this identifier to cite or link to this item:http://hdl.handle.net/2066/201063   http://hdl.handle.net/2066/201063
Display more details

Upload full text

Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.